再鼎医药（纳斯达克代码：ZLAB）报告季度损失为每股$(0.80)，这比去年同期每股$(0.98)的损失增加了18.37%。公司报告季度销售额为$109.07百万，超出分析师一致预期的$108.17百万，超出0.83%。这比去年同期的$65.83百万的销售额增加了65.68%。
以上内容来自Benzinga Earnings专栏，原文如下：
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.80) per share. This is a 18.37 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $109.07 million which beat the analyst consensus estimate of $108.17 million by 0.83 percent. This is a 65.68 percent increase over sales of $65.83 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.